233 Studies Now Enrolling
Menu
Search
Status
Medical Condition
- Show all (1519)
- Addiction (14)
- Allergy, Asthma, & Immunology (12)
- All of Us Research Program - NIH (1)
- Autoimmune Disorders (26)
- Blood Disorders (33)
- Bone & Muscle (8)
- Cancer
(552)
- Bladder Cancer (12)
- Brain Cancer (12)
- Breast Cancer (58)
- Gastrointestinal (10)
- Gynecologic Cancer (28)
- Head and Neck Cancer (4)
- Kidney Cancer (7)
- Leukemia (61)
- Liver Cancer (3)
- Lung Cancer (57)
- Lymphoma (23)
- Multiple Myeloma (24)
- Pancreatic Cancer (5)
- Prostate Cancer (25)
- Sarcoma (23)
- Skin Cancer (26)
- Solid Tumors (36)
- (-) Thyroid Cancer (1)
- Uveal Melanoma (7)
- Child Development (4)
- COVID-19 (Coronavirus) (28)
- Critical Illness (1)
- Diabetes (15)
- Ear, Nose and Throat (5)
- Endocrine & Metabolic Disease (10)
- Eye (7)
- Gastrointestinal and Digestive Diseases (23)
- Hair and Skin Disorders (1)
- Headaches (5)
- Healthy Volunteers (143)
- Heart Disease (110)
- Infectious Disease (38)
- Insomnia (2)
- Kidney Disease (12)
- Liver Disease (40)
- Lung Disease (29)
- Meniere's Disease (1)
- Neurological Disorders (134)
- Nutrition (4)
- Obesity (1)
- Obstetrics & Gynecology (45)
- Pain Management (1)
- Pediatrics (86)
- Psychiatric Disorders (60)
- Rehabilitation (7)
- Stroke (5)
- Surgery (7)
- Transplant (36)
- Urology (4)
- Vascular Conditions (9)
Displaying 1 - 4 of 4
Condition: Cancer / Thyroid Cancer
Investigator: Antonio Fojo, MD, PhD
Status: Closed
This is a study designed for patients with medullary thyroid cancer. Treatment will consist of a drug called Ponatinib. Ponatinib is an investigational agent that blocks abnormal cancer proteins and therefore harms cancer cells. It was recently approved by the Food and Drug Administration for leukemia treatment, but is not approved for medullary thyroid…
Condition: Eye / Glaucoma
Investigator: Lama Al-Aswad, MD, MPH
Status: Closed
This study is for patients with Glaucoma. The purpose of this study is to investigate the safety and effectiveness of a study drug called Bimatoprost Sustained Release (SR) compared to treatment with eye drug Timolol. The Bimatoprost SR is an implant that is very small, is biodegradable (dissolves naturally in the body), and contains the bimatoprost drug.
Condition: Eye / Glaucoma
Investigator: Jeffrey Liebmann, MD
Status: Closed
Glaucoma is the leading cause of irreversible blindness worldwide. The most important test to detect progression is visual field testing. However, this test is very subjective, often unreliable, and variable. One of the main causes of unreliable tests is the lack of attentiveness or concentration during the test. Previous studies have shown that listening…
Research Study of New Treatment Called NT-501 (Encapsulated Cell Therapy (ECT) Implant) for Glaucoma
Condition: Eye / Glaucoma
Investigator: George Cioffi, MD
Status: Closed
Glaucoma is a given name of a group of diseases that affect the retinal ganglion cells in the eye and the optic nerve. Glaucoma cause degeneration of the retinal ganglion cells in the retina and their projections (axons) that form the optic nerve. Retinal ganglion cells and their axons transmit all of our vision information from the eye to the brain through…